SQUIRE, trial summary    PDF trial summary

A randomised clinical trial investigating the effect of versus in

        Z

NCT00981058    Lancet Oncol 2015;16:763-74  



Studied treatment
Control treatment



Patients
Group sizes-9 / -9



Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design



EndpointX1N1X0N0TE95% CI0,22,01,0

Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015;16:763-74     [PMID: 26045340]   link to pdf   add to Mendeley  

Links

ClinicalTrial.gov record NCT00981058



Registering number NCT00981058 (see trial on clinicaltrials.gov)
Code Name

 

All trials of

Appears in following systematic reviews: